PDCD1 and non-small cell lung carcinoma: Previous clinical trials involving advanced NSCLC patients have shown that the immune checkpoint blockade of Programmed cell Death-1 (PD-1), as well as Programmed cell Death-ligand 1 (PD-L1) provided better clinical outcomes for both PFS and OS, and fewer adverse effects when compared with standard chemotherapy13,14.